Literature DB >> 16377638

Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation.

Yasunari Takada1, Ann Gillenwater, Haruyo Ichikawa, Bharat B Aggarwal.   

Abstract

Because of its ability to suppress tumor cell proliferation, angiogenesis, and inflammation, the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) is currently in clinical trials. How SAHA mediates its effects is poorly understood. We found that in several human cancer cell lines, SAHA potentiated the apoptosis induced by tumor necrosis factor (TNF) and chemotherapeutic agents and inhibited TNF-induced invasion and receptor activator of NF-kappaB ligand-induced osteoclastogenesis, all of which are known to require NF-kappaB activation. These observations corresponded with the down-regulation of the expression of anti-apoptotic (IAP1, IAP2, X chromosome-linked IAP, Bcl-2, Bcl-x(L), TRAF1, FLIP, and survivin), proliferative (cyclin D1, cyclooxygenase 2, and c-Myc), and angiogenic (ICAM-1, matrix metalloproteinase-9, and vascular endothelial growth factor) gene products. Because several of these genes are regulated by NF-kappaB, we postulated that SAHA mediates its effects by modulating NF-kappaB and found that SAHA suppressed NF-kappaB activation induced by TNF, IL-1beta, okadaic acid, doxorubicin, lipopolysaccharide, H(2)O(2), phorbol myristate acetate, and cigarette smoke; the suppression was not cell type-specific because both inducible and constitutive NF-kappaB activation was inhibited. We also found that SAHA had no effect on direct binding of NF-kappaB to the DNA but inhibited sequentially the TNF-induced activation of IkappaBalpha kinase, IkappaBalpha phosphorylation, IkappaBalpha ubiquitination, IkappaBalpha degradation, p65 phosphorylation, and p65 nuclear translocation. Furthermore, SAHA inhibited the NF-kappaB-dependent reporter gene expression activated by TNF, TNFR1, TRADD, TRAF2, NF-kappaB-inducing kinase, IkappaBalpha kinase, and the p65 subunit of NF-kappaB. Overall, our results indicated that NF-kappaB and NF-kappaB-regulated gene expression inhibited by SAHA can enhance apoptosis and inhibit invasion and osteoclastogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16377638     DOI: 10.1074/jbc.M507213200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  γ-Tocotrienol but not γ-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents.

Authors:  Ramaswamy Kannappan; Vivek R Yadav; Bharat B Aggarwal
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

2.  Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma.

Authors:  Alexander Beck; Corinna Eberherr; Michaela Hagemann; Stefano Cairo; Beate Häberle; Christian Vokuhl; Dietrich von Schweinitz; Roland Kappler
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

3.  A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.

Authors:  Theodoros N Teknos; J Grecula; A Agrawal; M O Old; E Ozer; R Carrau; S Kang; J Rocco; D Blakaj; V Diavolitsis; B Kumar; P Kumar; Q Pan; M Palettas; L Wei; R Baiocchi; P Savvides
Journal:  Invest New Drugs       Date:  2018-12-19       Impact factor: 3.850

4.  Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.

Authors:  Susan E Bates; Robin Eisch; Alexander Ling; Douglas Rosing; Maria Turner; Stefania Pittaluga; H Miles Prince; Mark H Kirschbaum; Steven L Allen; Jasmine Zain; Larisa J Geskin; David Joske; Leslie Popplewell; Edward W Cowen; Elaine S Jaffe; Jean Nichols; Sally Kennedy; Seth M Steinberg; David J Liewehr; Louise C Showe; Caryn Steakley; John Wright; Tito Fojo; Thomas Litman; Richard L Piekarz
Journal:  Br J Haematol       Date:  2015-04-19       Impact factor: 6.998

5.  Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA.

Authors:  Longgui Wang; Xuanyi Zou; Aaron D Berger; Christian Twiss; Yi Peng; Yirong Li; Jason Chiu; Hongfeng Guo; Jaya Satagopan; Andrew Wilton; William Gerald; Ross Basch; Zhengxin Wang; Iman Osman; Peng Lee
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

6.  Trichostatin A enhances proliferation and migration of vascular smooth muscle cells by downregulating thioredoxin 1.

Authors:  Seungjeong Song; Sang Won Kang; Chulhee Choi
Journal:  Cardiovasc Res       Date:  2010-01-01       Impact factor: 10.787

7.  Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma.

Authors:  Ken-Ichi Kitazoe; Masahiro Abe; Masahiro Hiasa; Asuka Oda; Hiroe Amou; Takeshi Harada; Ayako Nakano; Kyoko Takeuchi; Toshihiro Hashimoto; Shuji Ozaki; Toshio Matsumoto
Journal:  Int J Hematol       Date:  2008-12-18       Impact factor: 2.490

8.  Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator.

Authors:  Sai Murali Krishna Pulukuri; Bharathi Gorantla; Jasti S Rao
Journal:  J Biol Chem       Date:  2007-10-08       Impact factor: 5.157

9.  Selective, potent blockade of the IRE1 and ATF6 pathways by 4-phenylbutyric acid analogues.

Authors:  Hui Zhang; Shotaro Nakajima; Hironori Kato; Liubao Gu; Tatsuya Yoshitomi; Kaoru Nagai; Hideyuki Shinmori; Susumu Kokubo; Masanori Kitamura
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

10.  High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo.

Authors:  Annika Lehmann; Carsten Denkert; Jan Budczies; Ann-Christin Buckendahl; Silvia Darb-Esfahani; Aurelia Noske; Berit Maria Müller; Marcus Bahra; Peter Neuhaus; Manfred Dietel; Glen Kristiansen; Wilko Weichert
Journal:  BMC Cancer       Date:  2009-11-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.